#pharmacyeducationcorner
Good afternoon everyone this is sara arakinis your clinical pharmacist welcome to episode number 204 of pharmacists education corner today i’ll be discussing another medication in summary for you the name of the medication is a neuro ellipta or umichlidinium and bilanteral inhalation powder combination this medication is from gsk pharma it was fda approved announced
On december 18 2013. i’ve included a picture of neuro elliptic over here for you to see and i’ll get into the dosing in a second but before that a neural elliptic is a combination of umichlidinium and anticholinergic and valentino a long-acting betadoadrangic agonist or laba indicated for the treatment of maintenance treatment of patients with chronic obstructive
Pulmonary disease or copd as far as mechanism of action goes human canadian is a long-acting masculinity antagonist often also known as anticholinergic and velenterol is a long-acting beta allergic agonist or lava as far as dosing goes it comes in an inhalation powder inhaler containing two foil blisters strips of powder formulation for oral inhalation uh one
Strip contains humid clay genome twenty sixty two point five microgram per blister and the other contains will enter around 25 microgram per blister as far as administration goes it’s for oral inhalation only maintenance treatment of copd is one inhalation of neurolepta once daily as far as side effects is seen in most of the clinical trials it included sinusitis
Lower respiratory infections constipation diarrhea pain in extremities muscle spasm neck pain or chest pain it’s very important for the pharmacist to know about the side effects and um to educate the patients especially taking a neurolepta for the first time and if they if the patient experience any side effects similar to these to refer back to the pharmacist or
Clinical specialist for follow-up the clinical programs for neuro ellipta included in 8138 subjects with copd in four six months long function trials a one a 12 month long term safety study and nine other trials of shorter durations a total of um 1124 subjects had had received at least one dose of neuroelephant um in the clinical trials and 1330 subjects have
Received a higher dose of humic clinium will enter in the studies the safety data in these studies are based on four six months and one twelve months trial so based on this trials um and studies a neuro ellipta humecradium plus bilantero inhalation powder was approved from gsk pharma on december 18 2013 and as a combination inhaler indicated for the maintenance
Treatment of patients with copd this is some information but neuro ellipta for more detailed information please refer back to the gsk website um under neuro ellipta it’s um and it’s um you can um look at the package insert which contains more information about the limitations of use side effects and dosing and other information about this medication hope you
Enjoyed this video as always stay safe and take your medications
Transcribed from video
Anoro Ellipta- COPD- by Saro Arakelians, PharmD- Episode # 204 By Pharmacist Education Corner- by Saro Arakelians
